Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
16-30 of 339
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
MinuteCE®Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Neal Ready, MD, PhD
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
MinuteCE®The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
MinuteCE®Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
The Evidence Base: Key Trials and Emerging Data
MinuteCE®The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
- advertisement
From Data to Decision: Patient Selection and Real-World Application
MinuteCE®From Data to Decision: Patient Selection and Real-World Application
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
The Power of Timing: Therapies That Change Outcomes
MinuteCE®The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
Novel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
CME/CENovel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
Alexandria May, PharmD, BCPS
Helena A. Yu, MD
Vicki Sherry, DNP, ANP-BC, AOCNP
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
